Pandemic influenza A vaccination and incidence of Guillain-Barré syndrome in Korea

Vaccine

Volumn 33, Issue 15, 2015, Pages 1815-1823

  Kim, Changsoo ^a   Rhie, Seonkyeong ^b   Suh, Mina ^c   Kang, Dae Ryong ^a   Choi, Yoon Jung ^d   Bae, Geun Ryang ^e   Choi, Young Chul ^f   Jun, Byung Yool ^g   Lee, Joon Soo ^h  

^a Yonsei University College of Medicine   (South Korea)

^b CHA University   (South Korea)

^c National Cancer Center   (South Korea)

^d Health Insurance Review Agency   (South Korea)

^e Korea Centers for Disease Control and Prevention   (South Korea)

^f Yonsei University College of Medicine   (South Korea)

^g Yonsei University   (South Korea)

^h Yonsei University College of Medicine   (South Korea)

Author keywords

Guillain Barr syndrome; Incidence rate; Influenza; Vaccination

Indexed keywords

ANTIVIRUS AGENT; INFLUENZA VACCINE; MIFAMURTIDE;

ADULT; AGED; ARTICLE; DISEASE SURVEILLANCE; EMERGENCY CARE; FEMALE; GROUPS BY AGE; GUILLAIN BARRE SYNDROME; HUMAN; INCIDENCE; INFLUENZA A (H1N1); INFLUENZA VACCINATION; KOREA; MAJOR CLINICAL STUDY; MALE; MASS IMMUNIZATION; MEDICAL RECORD REVIEW; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; PANDEMIC INFLUENZA; PRIORITY JOURNAL; RISK FACTOR; YOUNG ADULT; ADOLESCENT; ADVERSE EFFECTS; GUILLAIN-BARRE SYNDROME; HEALTH SURVEY; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INFLUENZA, HUMAN; PANDEMIC; SOUTH KOREA;

ADOLESCENT; ADULT; AGED; FEMALE; GUILLAIN-BARRE SYNDROME; HUMANS; INCIDENCE; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MASS VACCINATION; MIDDLE AGED; PANDEMICS; POPULATION SURVEILLANCE; REPUBLIC OF KOREA; YOUNG ADULT;

EID: 84925342509     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.02.035     Document Type: Article

References (41)

1. Hughes R.A., Cornblath D.R. Guillain-Barre syndrome. Lancet 2005, 366:1653-1666.
2. Korinthenberg R., Schessl J., Kirschner J. Clinical presentation and course of childhood Guillain-Barre syndrome: a prospective multicentre study. Neuropediatrics 2007, 38:10-17.
3. Hughes R.A., Rees J.H. Clinical and epidemiologic features of Guillain-Barre syndrome. J Infect Dis 1997, 176(Suppl 2):S92-S98.
4. Schonberger L.B., Bregman D.J., Sullivan-Bolyai J.Z., Keenlyside R.A., Ziegler D.W., Retailliau H.F., et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol 1979, 110:105-123.
5. Wu J., Xu F., Lu L., Lu M., Miao L., Gao T., et al. Safety and effectiveness of a 2009 H1N1 vaccine in Beijing. N Engl J Med 2010, 363:2416-2423.
6. Yih W.K., Lee G.M., Lieu T.A., Ball R., Kulldorff M., Rett M., et al. Surveillance for adverse events following receipt of pandemic 2009 H1N1 vaccine in the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) System, 2009-2010. Am J Epidemiol 2012, 175:1120-1128.
7. Dieleman J., Romio S., Johansen K., Weibel D., Bonhoeffer J., Sturkenboom M. Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe. BMJ 2011, 343:d3908.
8. Wise M.E., Viray M., Sejvar J.J., Lewis P., Baughman A.L., Connor W., et al. Guillain-Barre syndrome during the 2009-2010 H1N1 influenza vaccination campaign: population-based surveillance among 45 million Americans. Am J Epidemiol 2012, 175:1110-1119.
9. Shaikh A.G., Termsarasab P., Nwankwo C., Rao-Frisch A., Katirji B. Atypical forms of Guillain-Barre syndrome and H1N1-influenza vaccination. Vaccine 2012, 30:3251-3254.
10. Greene S.K., Rett M., Weintraub E.S., Li L., Yin R., Amato A.A., et al. Risk of confirmed Guillain-Barre syndrome following receipt of monovalent inactivated influenza A (H1N1) and seasonal influenza vaccines in the Vaccine Safety Datalink Project, 2009-2010. Am J Epidemiol 2012, 175:1100-1109.
11. De Wals P., Deceuninck G., Toth E., Boulianne N., Brunet D., Boucher R.M., et al. Risk of Guillain-Barre syndrome following H1N1 influenza vaccination in Quebec. JAMA 2012, 308:175-181.
12. Dodd C.N., Romio S.A., Black S., Vellozzi C., Andrews N., Sturkenboom M., et al. International collaboration to assess the risk of Guillain Barre Syndrome following Influenza A (H1N1) 2009 monovalent vaccines. Vaccine 2013, 31:4448-4458.
13. Choe Y.J., Cho H., Bae G.R., Lee J.K. Guillain-Barre syndrome following receipt of influenza A (H1N1) 2009 monovalent vaccine in Korea with an emphasis on Brighton Collaboration case definition. Vaccine 2011, 29:2066-2070.
14. Kim J.H., Cho H.Y., Hennessey K.A., Lee H.J., Bae G.R., Kim H.C. Adverse events following immunization (AEFI) with the novel influenza a (H1N1) 2009 vaccine: findings from the national registry of all vaccine recipients and AEFI and the passive surveillance system in South Korea. Jpn J Infect Dis 2012, 65:99-104.
15. Sejvar J.J., Kohl K.S., Gidudu J., Amato A., Bakshi N., Baxter R., et al. Guillain-Barre syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2011, 29:599-612.
16. Wood S.N. Fast stable restricted maximum likelihood and marginal likelihood estimation of semiparametric generalized linear models. J R Stat Soc Ser B 2011, 73:3-36.
17. Schwartz J. The distributed lag between air pollution and daily deaths. Epidemiology 2000, 11:320-326.
18. Alshekhlee A., Hussain Z., Sultan B., Katirji B. Guillain-Barre syndrome: incidence and mortality rates in US hospitals. Neurology 2008, 70:1608-1613.
19. Prevots D.R., Sutter R.W. Assessment of Guillain-Barre syndrome mortality and morbidity in the United States: implications for acute flaccid paralysis surveillance. J Infect Dis 1997, 175(Suppl 1):S151-S155.
20. Shui I.M., Rett M.D., Weintraub E., Marcy M., Amato A.A., Sheikh S.I., et al. Guillain-Barre syndrome incidence in a large United States cohort (2000-2009). Neuroepidemiology 2012, 39:109-115.
21. Stowe J., Andrews N., Wise L., Miller E. Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenza like illness using the United Kingdom General Practice Research Database. Am J Epidemiol 2009, 169:382-388.
22. Coe C.J. Guillain-Barre syndrome in Korean children. Yonsei Med J 1989, 30:81-87.
23. Lehmann H.C., Hartung H.P., Kieseier B.C., Hughes R.A. Guillain-Barre syndrome after exposure to influenza virus. Lancet Infect Dis 2010, 10:643-651.
24. Rees J.H., Soudain S.E., Gregson N.A., Hughes R.A. Campylobacter jejuni infection and Guillain-Barre syndrome. N Engl J Med 1995, 333:1374-1379.
25. Jacobs B.C., Rothbarth P.H., van der Meche F.G., Herbrink P., Schmitz P.I., de Klerk M.A., et al. The spectrum of antecedent infections in Guillain-Barre syndrome: a case-control study. Neurology 1998, 51:1110-1115.
26. Huang W.T., Yang H.W., Liao T.L., Wu W.J., Yang S.E., Chih Y.C., et al. Safety of pandemic (H1N1) 2009 monovalent vaccines in Taiwan: a self-controlled case series study. PloS ONE 2013, 8:e58827.
27. Romio S., Weibel D., Dieleman J.P., Olberg H.K., de Vries C.S., Sammon C., et al. Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines: a multinational self-controlled case series in Europe. PLOS ONE 2014, 9:e82222.
28. Prestel J., Volkers P., Mentzer D., Lehmann H.C., Hartung H.P., Keller-Stanislawski B., et al. Risk of Guillain-Barre syndrome following pandemic influenza A (H1N1) 2009 vaccination in Germany. Pharmacoepidemiol Drug Saf 2014, 23:1192-1204.
29. Salmon D.A., Proschan M., Forshee R., Gargiullo P., Bleser W., Burwen D.R., et al. Association between Guillain-Barre syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. Lancet 2013, 381:1461-1468.
30. Greene S.K., Kulldorff M., Lewis E.M., Li R., Yin R., Weintraub E.S., et al. Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project. Am J Epidemiol 2010, 171:177-188.
31. Choe Y.J., Cho H., Kim S.N., Bae G.R., Lee J.K. Serious adverse events following receipt of trivalent inactivated influenza vaccine in Korea, 2003-2010. Vaccine 2011, 29:7727-7732.
32. Sivadon-Tardy V., Orlikowski D., Rozenberg F., Caudie C., Sharshar T., Lebon P., et al. Guillain-Barre syndrome, greater Paris area. Emerg Infect Dis 2006, 12:990-993.
33. Tam C.C., O'Brien S.J., Petersen I., Islam A., Hayward A., Rodrigues L.C. Guillain-Barre syndrome and preceding infection with campylobacter, influenza and Epstein-Barr virus in the general practice research database. PloS ONE 2007, 2:e344.
34. Grimaldi-Bensouda L., Alperovitch A., Besson G., Vial C., Cuisset J.M., Papeix C., et al. Guillain-Barre syndrome, influenza like illnesses, and influenza vaccination during seasons with and without circulating A/H1N1 viruses. Am J Epidemiol 2011, 174:326-335. (Epub 2011 Jun 7).
35. Sivadon-Tardy V., Orlikowski D., Porcher R., Sharshar T., Durand M.C., Enouf V., et al. Guillain-Barre syndrome and influenza virus infection. Clin Infect Dis 2009, 48:48-56.
36. Chaari A., Bahloul M., Dammak H., Nourhene G., Rekik N., Hedi C., et al. Guillain-Barre syndrome related to pandemic influenza A (H1N1) infection. Intensive Care Med 2010, 36:1275.
37. Vellozzi C., Iqbal S., Stewart B., Tokars J., DeStefano F. Cumulative risk of Guillain-Barre syndrome among vaccinated and unvaccinated populations during the 2009 H1N1 influenza pandemic. Am J Public Health 2014, 104:696-701.
38. Kwong J.C., Crowcroft N.S., Wilson K., McGeer A.J., Deeks S.L. Influenza vaccination and Guillain-Barre syndrome. Lancet Infect Dis 2014, 14:369-370.
39. Isai A., Durand J., Le Meur S., Hidalgo-Simon A., Kurz X. Autoimmune disorders after immunisation with Influenza A/H1N1 vaccines with and without adjuvant: EudraVigilance data and literature review. Vaccine 2012, 30:7123-7129.
40. Black S., Eskola J., Siegrist C.A., Halsey N., Macdonald N., Law B., et al. Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet 2009, 374:2115-2122.
41. McGrogan A., Madle G.C., Seaman H.E., de Vries C.S. The epidemiology of Guillain-Barre syndrome worldwide. A systematic literature review. Neuroepidemiology 2009, 32:150-163.